A Phase Ib/Ii, Open-Label, Multicenter Study With A Non-Randomized Stage Evaluating The Safety, Pharmacokinetics, And Efficacy Of Mosunetuzumab Plus Lenalidomide (+ Len), And A Randomized Stage Evaluating The Safety, Tolerability, And Pharmacokinetic